Thomas N. Kledal

Copenhagen, 1360, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Promiscuous binding of CXC chemokines to ORF74 receptors enables immunotoxin approaches in Gammaherpesvirus models.

Promiscuous binding of CXC chemokines to ORF74 receptors enables immunotoxin approaches in Gammaherpesvirus models.

Journal: Biochemical pharmacology

Published: March 03, 2026

Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin.

Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: September 22, 2025

Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin.

Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: September 22, 2025

Targeting of Kaposi's sarcoma-associated herpesvirus by immunotoxins directed against the viral G protein-coupled receptor, ORF74.

Targeting of Kaposi's sarcoma-associated herpesvirus by immunotoxins directed against the viral G protein-coupled receptor, ORF74.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 24, 2025

Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial.

Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: April 27, 2023

Publisher Correction: Reply to: How many SARS-CoV-2 "viroporins" are really ion channels?

Publisher Correction: Reply to: How many SARS-CoV-2 "viroporins" are really ion channels?

Journal: Communications biology

Published: September 28, 2022

The antiviral targeting potential of viroporins

The antiviral targeting potential of viroporins

Journal: Ugeskrift for laeger

Published: June 15, 2022

Reply to: How Many SARS-CoV-2 "Viroporins" Are Really Ion Channels?

Reply to: How Many SARS-CoV-2 "Viroporins" Are Really Ion Channels?

Journal: Communications biology

Published: March 09, 2022

Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro.

Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro.

Journal: Communications biology

Published: December 11, 2021

Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1.

Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1.

Journal: Cancers

Published: July 15, 2021

Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin.

Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin.

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Published: June 24, 2021

Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.

Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.

Journal: Communications biology

Published: December 02, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026